"Designing Growth Strategies is in our DNA"
In July 2018, ThromboGenics, Belgium based biotechnology company completed its first clinical trial of an antibody (THR-317) for the treatment of macular edema. Macular e... Read More
Region : Global | Published Date: Upcoming | Report ID: FBI101152 | Status : Upcoming